The Conversation (0)
Genocea Biosciences, Inc. Announces Pricing of $55 Million Concurrent Public Offerings
Jan. 19, 2018 08:55AM PST
Biotech InvestingGenocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company that discovers and develops novel cancer vaccines, announced today the pricing of concurrent underwritten public offerings of (i) 53,365,000 shares of its common stock and accompanying Class A warrants to purchase up to 26,682,500 shares of its common stock… As quoted in the press release: Cantor Fitzgerald & …
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company that discovers and develops novel cancer vaccines, announced today the pricing of concurrent underwritten public offerings of (i) 53,365,000 shares of its common stock and accompanying Class A warrants to purchase up to 26,682,500 shares of its common stock…
As quoted in the press release:
Cantor Fitzgerald & Co. is acting as the sole book-running manager for the concurrent offerings. Needham & Company, LLC and Robert W. Baird & Co. Incorporated are acting as the lead managers for the concurrent offerings. H.C. Wainwright & Co., LLC. is acting as co-manager for the concurrent offerings.